Brief: Comera Life Sciences Announces Favorable Preclinical Results Of Lead Sqore Excipient In Sequrus-2 Study

Comera Life Sciences Holdings

18/10/2022 13:03

Oct 18 (Reuters) - Comera Life Sciences Holdings Inc
 CMRA.O :
    * COMERA LIFE SCIENCES ANNOUNCES FAVORABLE PRECLINICAL
RESULTS OF
LEAD SQORE EXCIPIENT IN SEQURUS-2 STUDY
    * COMERA LIFE SCIENCES - SEQURUS-2 DATA SHOW NO EVIDENCE OF
LOCAL/SYSTEMIC TOXICITY OF CAFFEINE IN ANIMALS WHEN ADMINISTERED
SUBCUTANEOUSLY WITH IPILIMUMAB
    * COMERA LIFE SCIENCES HOLDINGS INC - DATA ALSO REVEAL NO
EVIDENCE
OF CAFFEINE IMPACT ON IPILIMUMAB ABSORPTION
    * COMERA LIFE SCIENCES - RESULTS ESTABLISH CAFFEINE HAD NO
IMPACT
ON IPILIMUMAB HALF-LIFE & NO EFFECT ON PHARMACOKINETIC DATA FOR
BOTH IV AND SQ GROUPS

Source text for Eikon:  ID:nGNX6wHlZj 
Further company coverage:  CMRA.O 
 ((Reuters.Briefs@thomsonreuters.com;))